European heart journal. Quality of care & clinical outcomes · 2026
Sustainable and effective lipid-lowering management: prevention strategies from the BRING-UP prevention study.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Colivicchi Furio, Temporelli Pier Luigi, Fattirolli Francesco, Abrignani Maurizio Giuseppe, Alonzo Alessandro, Arca Marcello, Averna Maurizio, Bertoli Daniele, Calabrò Paolo, Calò Leonardo, Carugo Stefano, Catapano Alberico Luigi, Ceseri Martina, Di Fusco Stefania Angela, Di Lenarda Andrea, Fabbri Gianna, Gulizia Michele Massimo, La Rosa Giuseppe, Lucci Donata, Maffei Simone, Navazio Alessandro, Oliva Fabrizio, Orso Francesco, Riccio Carmine, Scelza Nicola, Gabrielli Domenico, Maggioni Aldo Pietro, BRING-UP Prevention
Аннотация
AIMS: Adherence to guideline recommendations for secondary prevention appears to be inadequate, even in cardiology centres. To narrow the gap between guideline recommendations and what is implemented in clinical practice, we designed the BRING-UP Prevention project.
METHODS AND RESULTS: BRING-UP Prevention is a nationwide, observational, prospective, multicenter study enrolling patients with a prior atherothrombotic event. The study consists of two 3-month enrolment phases followed by a 6-month follow-up, with each phase preceded by an educational intervention. Data presented here mainly focus on the percentage of patients at goal for LDL-cholesterol (LDL-C) (<55 mg/dL) at the 6-month follow-up in the recently completed first enrolment phase. Secondary endpoints are blood pressure, glycaemic and weight control, and smoking cessation. Over 3 months, 189 cardiology centres recruited 4790 patients. Follow-up data at 6 months were available for 4643 patients (97%) and LDL-C was available for 4334 of them. The rate of patients with LDL-C < 55 mg/dL increased from 33% to 58.1%, with absolute and relative increases of 25.1% and 76.1%, respectively. At 6 months, 94.9% of patients were prescribed statins. Atorvastatin and rosuvastatin were the most prescribed statins, mostly at high doses. Ezetimibe was prescribed in 84% of cases. PCSK9i monoclonal antibodies and inclisiran were prescribed in 8.3% of patients.
CONCLUSION: BRING-UP prevention achieved its primary goal to increase the percentage of patients at the LDL-C goal, demonstrating that, in many patients, this goal can be achieved by increasing the use of low-cost therapies.
CLINICALTRIAL.GOV: NCT06275113.
METHODS AND RESULTS: BRING-UP Prevention is a nationwide, observational, prospective, multicenter study enrolling patients with a prior atherothrombotic event. The study consists of two 3-month enrolment phases followed by a 6-month follow-up, with each phase preceded by an educational intervention. Data presented here mainly focus on the percentage of patients at goal for LDL-cholesterol (LDL-C) (<55 mg/dL) at the 6-month follow-up in the recently completed first enrolment phase. Secondary endpoints are blood pressure, glycaemic and weight control, and smoking cessation. Over 3 months, 189 cardiology centres recruited 4790 patients. Follow-up data at 6 months were available for 4643 patients (97%) and LDL-C was available for 4334 of them. The rate of patients with LDL-C < 55 mg/dL increased from 33% to 58.1%, with absolute and relative increases of 25.1% and 76.1%, respectively. At 6 months, 94.9% of patients were prescribed statins. Atorvastatin and rosuvastatin were the most prescribed statins, mostly at high doses. Ezetimibe was prescribed in 84% of cases. PCSK9i monoclonal antibodies and inclisiran were prescribed in 8.3% of patients.
CONCLUSION: BRING-UP prevention achieved its primary goal to increase the percentage of patients at the LDL-C goal, demonstrating that, in many patients, this goal can be achieved by increasing the use of low-cost therapies.
CLINICALTRIAL.GOV: NCT06275113.